Hims & Hers Health, Inc. (HIMS) Earnings Call Transcript
November 3, 2025
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for joining the Hims & Hers Health Third Quarter 2025 Earnings Call. Earlier today, once the market had closed, we put out the shareholder letter for this quarter, and you can access a copy on our site at investors.hims.com. Joining me on this call are Andrew Dudum, our Co-Founder and Chief Executive Officer, and Yemi Okupe, our Chief Financial Officer. Before Andrew takes over, I must go over the legal safe harbor and cautionary declarations. A number of the statements and projections of future results included in this presentation are forward-looking statements, which rest on, among other things, our present expectations regarding the market, competitors and regulation, and they carry risks and uncertainties that might lead actual results to vary materially. We are under no obligation to publicly update any forward-looking statements following this call, whether because of new information, future events, changes in assumptions or otherwise. The risks, uncertainties and other factors that might lead actual results to differ from our forward-looking statements are laid out in our earnings release and SEC filings. For a discussion of these risk factors as they pertain to forward-looking statements, please look at our recent earnings release along with our most recently filed 10-K and 10-Q reports. In today's presentation, we also include certain non-GAAP financial measures; please refer to the reconciliation tables to the most directly comparable GAAP financial measures that appear in today's press release and shareholder letter. This information, along with a link to today's webcast, is available at investors.hims.com. Following the call, the webcast will remain archived on the website for 12 months. With that, I'll hand things over to Andrew.
Thanks, Bill. For Hims & Hers, Q3 marked yet another solid move ahead. The approach we've taken is delivering results. We're broadening our footprint, building deeper connections, and changing the way individuals go through health care; and what's most thrilling is that as our scale grows, the whole experience gets better for our subscribers. Among the limited number of health care platforms where every single customer interaction enhances the overall experience is Hims & Hers. Getting bigger isn't the only thing scale does — it also makes us improve. What we take away from every encounter puts us in position to create improved experiences, more robust customer ties, and greater accessibility. At the heart of this transformation lies personalized care. Since we keep getting bigger, a greater number of people are able to receive care plans that can be tailored to their own specific requirements, biology, and objectives by drawing on a variety of form factors, dosing schedules, and solutions addressing multiple conditions. Our ongoing commitment to making these kinds of experiences accessible to everyone continues to deliver meaningful results for the business. As the quarter came to an end, the number of subscribers using personalized offerings had climbed 50% compared with the same period a year earlier, which contributed to revenue growth of nearly 50% year-over-year. The manner in which we serve our customers has undergone extraordinary changes during the last several years. In the beginning, we assisted people in obtaining straightforward, effective treatments for a small number of conditions. After that, we moved into personalized multi-condition care, offering customers one location to handle a broad range of health challenges with solutions customized for them. Now, as we look forward, our plan is to move past merely helping individuals treat conditions they already have and begin assisting them in proactively managing their health even before conditions arise. As we keep constructing a platform that opens up wider access to care that is personal, proactive, and connected, we anticipate that broader collaboration is going to be essential. Be it via partnerships, investments, or joint innovation, we perceive tremendous potential in collaborating with others throughout the health care ecosystem to bring this future about. As we mentioned in our earnings release, we are currently in active discussions with Novo Nordisk to bring Wegovy injections and, once the FDA approves it, Novo's oral Wegovy to our platform so consumer options keep advancing. Earlier in the quarter, we revealed a partnership with Marius Pharmaceuticals, which will let our customers obtain one of the limited number of FDA-approved oral testosterone treatments in 2026. We believe these solutions, paired with steady provider support and the capacity to track hormone levels seamlessly through the Hims app, can help reshape the way millions of men obtain effective hormonal care. Not long ago, we put money into GRAIL as a strategic move — that's the business behind the multi-cancer early detection test we regard as the most advanced one you can get today, and supporting a firm whose future vision aligns with ours makes us proud. What we've been building shows its promise through these kinds of relationships. They also show we remain dedicated to evolving our platform into a robust curator of best-in-class health and wellness solutions. Going forward, our plan is to bring together strategic investments, partnerships and collaborations, allowing us to build a single destination where customers can discover a range of innovative offerings alongside care that is the most personal and convenient available. The recent developments offer a thrilling glimpse into a future where preventive, proactive care is the norm instead of something only some can access. I've never been more enthusiastic about where this company is headed. When we initially introduced our 2030 targets earlier this year — over $6.5 billion in revenue along with $1.3 billion in adjusted EBITDA — that清晰 vision was steering us. Now we're making that vision a tangible reality. Opportunities to accelerate our progress are emerging more quickly than anticipated, and we're fully committing. Let's start with weight loss, which remains among the most significant global health issues, impacting close to 1 billion adults around the world. In the roughly two years since this specialty became part of our offerings, we've shown that when you combine dependable access to medications that work with an experience that's best-in-class, people's lives can genuinely improve. Our conviction is that customers see the greatest benefit when they receive provider recommendations grounded in data, continuous clinical support, and digital tools that are simple to use for monitoring their progress. Underpinning our ability to keep growing is the fact that we continue to bring our compounding infrastructure further in-house vertically. We're of the view that the money we put into these facilities is establishing a fresh benchmark of excellence for compounding infrastructure as a whole, which puts us in position to speed up growth while upholding the rigorous safety, quality, and affordability standards our customers expect. A key point here: every active pharmaceutical ingredient used in compounded treatments comes from facilities that are FDA-registered. Take semaglutide as one example. The FDA has now put together a green list of GLP-1 API suppliers, and when that list applies, those suppliers are the only ones we buy from. Our scale has increased, and along the way we've demonstrated that we can reliably turn that bigger scale into better efficiency. That history, plus the work we keep doing to verticalize our sterile compounding operations, backs our continued push to make GLP-1 offerings more and more accessible. Not long ago, we made a strategic decision to cut prices on compounded GLP-1 treatment plans by up to 20%, which brings accessible care to a wider group of people. Over the coming quarters, we'll keep broadening the range of options people can reach through our platform. Thanks to our tech and our vertically integrated infrastructure, we're reaching fresh heights in personalization — the latest example being microdosing choices now available for compounded semaglutide treatments. That capability lets us provide what we consider the market's most hands-on, patient-focused experience. And as we assist a growing number of customers in locating the appropriate treatment and in supporting providers through changing patient care, we keep reinforcing that leading role. To put it plainly, we're removing obstacles so that more customers can begin, remain consistent with, and achieve success in their personal weight loss efforts, and we're sure we'll keep producing results for an expanding customer base by doing this; we're also bringing the advantages of our consumer-first strategy into additional specialties. We think the launches we've rolled out lately — for low testosterone and for menopause — open up major opportunities to grow over the long haul, and they boost our capacity to build deeper ties with the subscribers we already have while bringing care within reach for millions more people. When you look at where hormone health care stands right now in the U.S., it mirrors precisely the problem Hims & Hers came into existence to solve: conditions affecting millions, treatment choices that genuinely help, and a system that keeps access much too difficult; that's what we're fixing. A huge number of men deal with low testosterone symptoms, yet they run into stigma, uncertainty, or few paths to effective care. With our latest launch, the goal is to tackle those problems by giving people personalized, provider-guided treatment plans backed by lab testing done at home. It's still early days, but the reaction so far signals an instant fit between the product and the market, and we're busy fine-tuning the experience as well as the operational machinery behind the offering so we can keep up with such strong demand. With what we offer for perimenopause and menopause, we're taking on one of the largest unmet needs in women's health. About 1.3 million women across the U.S. start menopause annually, and yet just 30% of OB/GYN residency programs provide formal instruction in treating it. Our new Hers offering works to bridge that gap, delivering personalized care and support built specifically for women going through this life stage.
We anticipate that this new offering will turn into a substantial growth engine, given that the Hers brand is connecting with a greater number of women and moving toward reaching $1 billion in yearly revenue during 2026. Taken together, these product introductions widen our reach across various life stages and health conditions, and even more crucially, they establish the basis for the coming period in which Hims & Hers can disrupt the existing situation for millions of customers, proactive health and diagnostics. We intend to introduce full whole body lab testing prior to the close of the year, which will mark a major advance in this progression. By growing services such as blood testing, we are delighted to assist additional customers in gaining affordable access to the information they require to track, sustain and enhance their general wellness. We picture these services enabling consumers to tackle health issues proactively, for example vitamin deficiencies, unoptimized hormonal levels and genetic risk factors, while at the same time spotting early signs of more severe conditions such as cancer and cardiovascular disease. In the past, individuals have turned to us to handle conditions they already had. Before long, we will assist them in assuming a more proactive part in overseeing their health, and by doing so, could potentially affect millions of lives. Our aim is that someday we will help detect and manage risks tied to heart disease, metabolic disorders, neurodegenerative diseases and cancer, well before any symptoms show up; we think our platform holds a distinctive advantage to bring this about. We possess the lab testing abilities to provide customers and providers with deeper health information. We have the provider network and compounding infrastructure ready to help act on that information, and we have an increasingly strong data feedback loop that can assist in measuring, adjusting and honing care at scale; we think that mix puts Hims & Hers in a position to accomplish what very few others in health care are able to, converting data into customized action for millions of individuals. These abilities, along with our peptide manufacturing facility located in California, which is actively bringing R&D for core peptide applications back onshore, constitute the basis of the longevity specialty we intend to introduce in 2026; we intend to grow the specialty so it offers a wide array of therapies in addition to our new testing choices. As time goes on, we anticipate these will encompass peptides, coenzymes, GLP and GIP treatments crafted to boost performance, recovery and cardiometabolic longevity markers. Every one of these efforts forms part of a wider push to make sophisticated diagnostics and the care that ensues more within reach. Via investment and, where suitable, partnerships, we anticipate this kind of care, which in the past has been within reach only of a small wealthy segment of the population, will become available to all our customers. Lastly, our achievements in the U.S; and U.K. provide us with genuine confidence that our model can expand on a global scale. We think that this team, vision and balance sheet we currently have are distinctively suited to grow a top consumer health platform worldwide. Over in Europe, thanks to picking up Zava Global, we've got the infrastructure in place to serve customers throughout the U.K., Germany, France, Ireland, and Spain. Across those regions, we now reach a total addressable market exceeding 200 million adults, and the initial feedback keeps confirming how easily our model carries over. Moving on, we're getting set to enter Canada before long, which will notably expand our footprint in North America. Given that 2/3 of adults in Canada are either overweight or dealing with obesity, we couldn't be more excited about the chance to make high-touch care easier to reach. Right now we're in active talks with top generic manufacturers so that when semaglutide turns generic in 2026, we'll be positioned to provide access via our platform. Going forward, we view international markets as a strong long-term growth driver, worth more than $1 billion in possible yearly revenue; we're putting meaningful capital to work bringing the Hims & Hers experience to additional customers throughout the U.K. and across broader European markets, where a substantial opportunity exists to scale our model and strengthen our presence. Our belief is that Hims & Hers will before long be the biggest global consumer health platform, opening up access to direct-to-consumer personalized care for more customers than any other company worldwide. This philosophy carries through our whole business. The room for growth and the chances to drive faster adoption across a broad array of conditions and health concerns are obvious. We'll continue putting money into what matters most, widening our reach, building deeper engagement, and expanding our capabilities, so customers can manage and improve their health on one single platform. From the day I founded this company, I've never felt more excited than I do at this moment. Health care's future belongs to us to create, and we're creating it step by step. With that, I'll hand things to Yemi to walk through our financial performance and our updated outlook for 2025.
Thanks, Andrew. I'll begin with a look at how we performed financially in the third quarter, and then I'll take a closer look at what we expect for the full year 2025. During Q3, our dedication to delivering more value to our customers produced yet another stretch of remarkable growth and expansion. By regularly rolling out fresh, innovative products and extending the variety of specialties we serve, we keep methodically growing how many people we can connect with and assist; this widening scope of care, rooted in an approach built on precision medicine, lets us engage customers at numerous stages along their health care journey and adapt alongside them as their requirements shift. In Q3, revenue climbed 49% compared with the same period a year earlier, reaching just under $600 million, and adjusted EBITDA margins came in at over 13%. Our subscriber count rose by over 30,000 from the prior quarter during Q3, which works out to a 20% increase versus the year-ago period; we're seeing the emergence of a solid base of multiyear growth drivers spanning 3 primary parts of our portfolio: U.S. offerings under the Hims brand, U.S. offerings under the Hers brand, plus a growing set of international markets. Inside the Hims brand, we're intentionally working to shift away from generic on-demand sexual health solutions and toward more tailored daily treatment options, which let providers tackle a broader array of needs. Setting aside the effect of the sexual health transition currently underway, Q3 subscribers were up more than 40% from a year earlier. We anticipate that this transition's impact will fade substantially during the back half of next year. We think these dynamics, combined with rolling out new products like testosterone, will lead to faster growth during the back half of 2026 in our Hims portfolio. Turning to Hers. The combined offerings under the Hers brand have expanded at close to or beyond triple-digit rates over the past several years, and we're now on track to produce more than $1 billion of revenue in 2026; we anticipate that adding new specialties including menopause, diagnostics and longevity will keep fueling robust growth throughout the Hers portfolio. Before I go further into the investments we're making to fuel growth in our strategic areas, let me walk through the profitability picture. In Q3, adjusted EBITDA rose over 50% versus the prior year to $78 million, which stands as another strong evidence point of how well our team executes with discipline and delivers results in line with our capital allocation framework. Adjusted EBITDA margins came in higher than a year earlier, since considerable leverage on marketing spend more than made up for increased costs, and we keep gaining from investments that let us scale new specialties, broaden our worldwide presence and further strengthen the talent throughout the organization. Specifically, we're investing significantly in talent within our technology organization as we build the team and infrastructure to fuel our next stage of expansion. Marketing came to 39% of revenue, which represents over 6 points of leverage compared with a year ago. We keep seeing gains in acquisition via cheaper and unpaid routes, plus advantages from better retention as a growing number of subscribers take advantage of tailored options and a steadier environment in our weight loss segment. All of these elements have produced leverage, since revenue growth has been exceeding what we spend on marketing. Gross margins fell by more than 2 points versus the prior quarter, landing at 74%, because favorable trends from ongoing expansion in non-weight specialties were counterbalanced by reduced intra-quarter revenue recognized per shipment from certain weight loss offerings stemming from shorter shipping cadences. G&A costs likewise faced pressure stemming from the Zava integration, along with extra expenses tied to bringing on new leadership talent. G&A measured as a share of revenue rose 2 points compared with a year earlier. Operations and support costs displayed a comparable pattern. Technology and development costs, as a share of revenue, climbed close to 2 points versus the same period last year, reaching 7%, which mirrors sustained investment in engineering and product talent throughout the organization; we anticipate continuing to put money into this area in the quarters ahead, since these efforts improve the customer experience and generate long-term financial returns. We think these investments will be recouped across the mid- to long term through lower costs achieved via greater efficiency, but even more crucially, by opening up new growth vectors for the company down the road. Our focus is on generating free cash flow over the long term, and every investment we are making now lays the groundwork for stronger free cash flow generation later on; during the third quarter, cash flow from operations came to $149 million, which amounted to free cash flow of $79 million. As the quarter closed, we held more than $1.1 billion in cash, short-term and long-term investments, with $630 million of that sitting in cash and short-term investments. The power of our cash flow and balance sheet puts us in a distinctive spot to deploy capital strategically so we can grow both organically and by pursuing strategic M&A opportunities. We regard this as a significant differentiator and a chance to solidify our leadership position, since we don't think any peer in our space possesses the resources and expertise to accomplish the same. As in earlier quarters, we intend to invest in the following areas. The first is ongoing verticalization and enlargement of personalized capabilities inside our facilities. Over the next quarters, we anticipate that our operational footprint and capabilities will keep growing; we began the year with a facility footprint of just under 400,000 square feet and expect to finish the year with a footprint north of 1 million. That will let us unlock additional form factors such as gummies spanning a wider set of specialties, boost capacity for fulfillment of sterile offerings, and also leverage insights from diagnostic capabilities to deliver an even more comprehensive set of multi-condition offerings. Although we anticipate retention and acquisition gains in every one of our specialties, this element will matter especially when it comes to: first, making our sexual health offering appeal to more people as we shift away from on-demand products and toward daily solutions; and second, using verticalization so that more complex offerings, including our weight loss and testosterone solutions, become more affordable without giving up much margin over the long term. Next, our intention is to keep widening the range of solutions and improving the customer experience in our new specialties; during Q3, we were happy to introduce our low testosterone offering and strong interest has already come from our existing subscriber base; in Q4, we have rolled out solutions for perimenopause and menopause support and intend to launch comprehensive lab testing diagnostics, and we believe both will serve as meaningful accelerants for the business; we anticipate that ongoing investments in our facilities will let us expand solutions in these specialties and also lower the cost of verticalization. Third, strategic investments, partnerships and collaborations remain, in our view, powerful ways to extend our impact and push our mission forward. Our recent investment in GRAIL illustrates this approach. Via these initiatives, we see genuine opportunity to use our balance sheet to deepen relationships throughout the wider health care ecosystem.
As time goes on, these initiatives can help a wider share of people gain access to new and innovative health care developments. Next, we anticipate making substantial investments in what our technology platform is capable of. With the introduction of more advanced diagnostic testing among what we offer, we think the volume of data on our platform and how useful it is in assisting our subscribers to optimize their health will grow considerably. That might take the shape of recommendations for treatment based on data, chatbots that deliver faster nonclinical customer solutions or AI-assisted resources like nutritional coaches; early wins are already appearing, and we look forward to providing more in-depth updates on this area down the road. To wrap up, our purpose—enabling people everywhere to feel their best by way of improved health—knows no boundaries. The traction we achieved in the U.K. opened the door for us to enter Germany, France, Ireland, and Spain through the Zava deal, and Canada is set to be added to that group before long. Because our balance sheet remains strong and the U.S. has given us a robust cash flow foundation, we have the ability to deploy capital carefully across these earlier-stage markets. Beyond that, we expect to grow our U.K. business by a wide margin, putting more money into broadening what we can offer and elevating our brand, as the indicators we're seeing suggest a sizable opening. Further refinement of our strategy creates room for expansion into Brazil, Australia, and additional markets across Latin America and Asia down the road. Hims & Hers is undergoing another major transformation on several fronts: technology, fresh capabilities, new specialties, and an expanding geographic footprint. One of the most thrilling developments will come from what our upcoming release of full-body diagnostic testing makes possible. At present, people come to our platform seeking a remedy for a specific condition they want assistance with. By going deeper with diagnostics, we believe we can move toward a model where subscribers take a proactive role in managing their health as they chase longer, healthier lives. By doing this, we can attract a wider range of customers while also strengthening the relationship we have with our existing subscribers. Over the coming quarters, we plan to increase spending in order to unlock features that enhance what we offer to both today's subscribers and those who join us later. The money will go toward speeding up uptake in additional specialties, strengthening our engineering workforce so we can create a next-generation technology platform, and reinforcing our leadership standing through delivering more value to subscribers. Our approach to capital allocation will remain unchanged, and we are confident that, much like previous periods of investment, we will realize a substantial return on these outlays in the future. With that said, let me walk through what we're expecting for the remainder of the year. For Q4, we're projecting revenue in the range of $605 million to $625 million, reflecting growth of 26% to 30% compared to the same period last year. On adjusted EBITDA, we anticipate somewhere between $55 million and $65 million, which at the midpoint implies a 10% margin. Turning to the full year, we expect revenue to come in between $2.335 billion and $2.355 billion, marking a year-over-year increase of 58% to 59%. Full-year adjusted EBITDA should fall in the $307 million to $317 million range, equating to a 13% margin at the midpoint. This guidance is built on several assumptions. To start, with the fulfillment of sterile weight-loss items moving over to 503A sites, we're looking at a $20 million to $25 million drag in Q4. The reason is that shipments happen more frequently, so each one brings in less recognized revenue. As customer groups place refill orders and those build up, this pattern ought to settle down in the back half of 2026. We are directing substantial investment toward growing our in-house 503A sterile fulfillment capability. Because of how far we've come on that front, we felt confident enough to bring down the price points during Q4 on our GLP-1 offerings for 2-month, 4-month and 6-month durations, which makes them easier for people to obtain. Looking ahead, we anticipate some pressure on margins in the near term. That should even out during the back half of next year, as we continue pushing forward with making our sterile fulfillment operations more vertically integrated. Next, from Zava we continue to anticipate no less than $50 million in additional revenue during the latter six months of the year. Since that acquisition wrapped up in July, things have been moving strongly, and we are actively directing resources toward our established consumer-focused approach in order to capture the major market opportunities we see throughout Europe. Finally, we anticipate that softening in our on-demand sexual health segment will persist for now, but those challenges ought to start diminishing in 2026, when daily sexual health subscribers along with multi-condition treatment plans account for a larger portion of the overall mix. Personalization keeps moving forward as a major force behind keeping revenue around for the long haul, and it backs up the 85% or better goal we've set, while setting the company up for steadier recurring growth down the road. Like Andrew said, it's great to be in a spot where we can put money into our business's long-term path with confidence; those investments should kick off in Q4 and run through 2026 as we grow new categories, expand our footprint in additional markets and start delivering more value to subscribers via creative partnerships. That might mean a short break in margin expansion compared with last year, but we think these investments will significantly broaden how far our platform reaches across the globe. Given the enormous potential ahead of us, we stay very confident that we can hit or beat the 2030 goals we set earlier this year—at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. None of this would be achievable without the tremendous work done by Hims & Hers team members across the globe. I want to thank them, along with our subscribers and shareholders, for supporting our mission: helping people everywhere feel great by tapping into the power of better health. That said, I'll turn it back to Bill, who will kick off the Q&A with 2 questions from members of our retail investor community.
Appreciate that, Yemi, and my thanks as well to every investor who submitted questions across the weekend. Quite a few of those questions concerned the launches we have coming up for lab testing within our longevity offering. The one I have here is from Nick G. How long until you put out a complete stack subscription service that brings in at-home testing along with extra products and services such as peptides and a wider longevity offering? And what stands as the largest obstacles to a rollout of that kind?
Absolutely. Nick, I appreciate you raising that — it's a terrific question. Both of those 2 categories have us genuinely thrilled. Like we said during the prepared remarks, whole body lab testing is going to hit the platform very soon, ahead of the end of the year. To me personally, this one is truly exciting. What I'm talking about is a group of tests that, in the past, ran my family and me somewhere between $5,000 and $10,000 for that kind of comprehensive panel, and we're going to introduce it at just a tiny slice of that price; so it's a remarkably strong chance to create genuine equalization, letting anyone out there understand where their body stands, where their family and the people they care about stand, and making sure they stay in front of problems they don't yet know about. This testing, I believe, serves as the groundwork for the longevity specialty we referenced, which is, once again, a genuinely exciting new category. That specialty arrives on the market in 2026, and it will span a very broad array of treatments, including on-market peptides, coenzymes, GLP, GIP treatments, and all of it will be crafted and formulated around performance, recovery, and cardiometabolic longevity markers as the central optimization focus. So this category, once again, is out front when it comes to health and wellness; today only a very small number of people can get it; and I believe that great equalization, delivering it to more people, will prove remarkably powerful. Within this category, we're also hopeful that the current administration can assist in broadening access to additional peptides of this kind. There's, I think, an expanding roster of them, from BPC-157 and TB-500 to others, where studies are beginning to demonstrate genuine health and longevity advantages; and I think wider care in that area will simply be wonderful for customers. Another edge we hold in this category — and it's an exciting one — is that, as all of you recall, we bought the peptide manufacturing plant based in California, and that site is up, running, and operational, and right now it's onshoring a great deal of R&D that I believe will matter enormously for the huge variety of peptide-side options that will form part of this future category.
Appreciate that, Andrew. We've got a question now from the Hims House community, and it's about certain patterns showing up in the parts of our business where customers have been with us longer. Here's what they're asking: back earlier in this year, you said the core business was hitting or beating what we'd planned for. At this point it's obvious that in a handful of those areas, growth has begun slowing down. How much confidence do you have that core growth can get back to accelerating across the quarters ahead? Also, which particular levers are available for us to pull? And what's a realistic time line for those results to actually show up?
Yeah. Appreciate the question about Hims House. What we're seeing, I'd say, is a world that's changing quickly, with new specialties emerging, and those specialties increasingly blending into one another. As I think about some of the new capabilities coming later this year, like diagnostics, I believe that will only speed things up further. So more and more, each of the pieces we've described — and that Andrew walked through — along with the vision for where this company is headed, is genuinely turning into part of the core offering. We touched on this somewhat in the prepared remarks, but we increasingly view the business across a few strategic areas. First comes Hims U.S. Then there's our Hers U.S. business; and last, we see substantial opportunity internationally. When we consider just the scale and footprint of opportunities inside each of those strategic areas, we identify several growth vectors capable of not only sustaining strong growth, but possibly accelerating during the second half. So we have new specialties like testosterone under the Hims brand, or menopause and longevity under the Hers brand. And as we also begin shifting toward proactively helping consumers manage their care through lab diagnostics, I think these trends will only speed up. We discussed some near-term headwinds we're facing this year regarding the move toward daily sexual health consumers and away from on-demand sexual health users, plus some of the dynamics surrounding shorter weight loss cadences. As we begin turning the corner in the second half of the year, we stay very confident that both the Hims & Hers businesses will not only remain strong growth drivers, but could also potentially accelerate growth going forward.
Appreciate that, Yemi, and once more, thanks to all of you who submitted questions. So with that, I'll hand things back over to the operator so we can kick off the usual analyst Q&A.
Andrew, with diagnostics getting stronger, what kind of change do you expect in how quickly you can deliver treatments tailored to individuals and move into additional medical fields? Also, how would you tweak your advertising so that more buyers learn about this broader set of options?
Yeah. Excellent question, Justin. My belief is that the speed at which we launch new offerings will go up dramatically. Once you're able to grasp all sorts of things, ranging from insufficient nutrients to early markers of genetic predisposition, your capacity to reshape the product mix and individual items and make things extremely tailored to each person simply speeds up. So, as we mentioned during the prepared remarks, before this year finishes, we will exceed 1 million square feet of facilities, and we have truly established what I consider to be best-in-class, genuinely premium compounding operations. My expectation is that diagnostics unlock a genuine surge of possibilities for extreme personalization. On the advertising front, I believe this represents a major shift, and one that's quite thrilling. In the past, I'd say the company has leaned heavily toward direct-response advertising because of the deeply stigmatized ailments we address, correct — examples being hair loss, sexual health, and so forth. Once you begin moving into diagnostics, once you begin moving into longevity, whole body health, wellness, these are areas that you're eager to discuss. These are areas you're eager to tell the people you care about, correct? These are areas you're eager to tell your family about. Some of the items in this range are things I've personally purchased for my family over many years, simply because I want those closest to me to be able to get them. So I genuinely believe a truly structural shift is coming in the way the Hims & Hers brand appears, the sorts of messages that will be sent out. I believe this eventually creates strong long-term leverage for the company, which is quite thrilling, and it can also genuinely alter how people perceive what we do, correct? Rather than only showing up for short-term problems, I believe there's a chance here to create a worldwide platform where not just tens of millions, but hundreds of millions of individuals can depend on you to assist in getting ahead of health and assist in being proactive about health. And I believe you will truly observe that reflected in the evolution of the brand, the sorts of messages, and the sorts of venues where we appear.
I'd like to start by asking about how you're thinking about the mix of GLP-1 offerings available on the platform, particularly in the event that the Novo partnership goes ahead. Also, I suppose, might you bring in additional GLP-1 solutions into that specialty area? Then for my second question, could you discuss how price-sensitive consumers currently are when it comes to compounded GLP-1s? And in your view, what effect would lower prices have on demand?
Sure. Appreciate it, Maria. That's a really good question. I'll handle the first portion, and Yemi, perhaps you could take the second. Broadly speaking, my belief is that having breadth, a wide assortment, and options for patients is what wins. That's why we're pleased to be reengaging with Novo regarding the Wegovy pill, which we hope will receive FDA approval, along with the commercial dosing. My sense is that they, as well as others, will keep rolling out more innovation. Beyond that, there are clearly biotech developments sitting in Phase II and Phase III trials involving next-generation GLP-1, GIP dual and tri-agonist possibilities. Our position, then, is that breadth, assortment, and choice end up giving every individual a more personalized ability to achieve strong outcomes. As a result, you'll see us keep going after a broad range of treatments in this space. Broadly, it's unavoidable that partnerships of this kind — where we hold the position of the biggest consumer distribution platform in health care while others excel at delivering new therapeutic innovations to market — are something those sorts of companies ought to be pursuing together in the end. So my expectation is that you'll witness more of this across the ecosystem, though it's certainly an area where we devote a great deal of brain power and work to ensure that as next-generation advancements arrive, our relationships with the teams stay strong and they grasp the opportunities we can capture jointly.
Absolutely, and to address the latter portion of what you asked, Maria: our specialty in weight loss, I'd say, operates on much the same doctrine we've applied throughout our prior specialty areas. That doctrine is built on expanding scale, making things vertical, and afterward refining them while returning the value and savings to our subscribers. Consequently, in both our weight loss specialty — which includes the orals along with GLP-1s — we genuinely observe that the high-touch approach we maintain with providers is truly connecting with our subscribers. We're seeing solid retention throughout the platform. Our perspective is that, just as with other specialty areas we've pursued previously, once we can bring price points within easier reach for a wider set of users, that's going to let us keep attracting a larger audience. So we are noticing a few quite early encouraging indicators from certain recent adjustments we've implemented. We're eager to keep putting money into verticalizing our operations at a high-quality standard so we can keep returning those advantages to our subscribers.
Yeah. My first question concerns the Hers segment and that figure of roughly $1 billion in revenue for 2026. Could you discuss the timing around the new menopause offerings, and how significantly those might shift things? Or should we expect growth to come mostly from the products already on the market as we head into 2026?
Sure, I can address part of that, Craig, and Yemi, please chime in whenever. Hers, I'd say, has quite an attractive set of growth drivers; over the past two quarters or so we've mentioned a growth rate in the triple digits, roughly speaking; and I believe there's a genuine opportunity across the coming years for that kind of trajectory to be sustained. You have older categories — "older" — several years in existence within dermatology that continue expanding very rapidly. You also have, clearly, the oral weight offering, the personalized weight offering on the GLP side, which is expanding quite strongly. And then those newer areas in hormonal health, perimenopause plus longevity and diagnostics, I believe, will matter a great deal for women and this demographic. So it's a segment that, in my view, contains 4 or 5 distinct growth engines. It's likely among the more thrilling pieces of the business for me personally, simply because you get to watch the platform reach entirely new audiences, various ages, varying demographics, and wholly new therapeutic areas. Yet it's one where genuine diversity stems from how that growth is composed.
Absolutely, and I’ll piggyback on that with a few additional points, Craig. As the Hers platform has grown larger, I believe we’re also seeing our capacity to put money behind the brands in distinct ways keep rising higher and higher; and at this point, given the wider range of offerings we now have in areas such as mental health, support for menopause, air, weight, and diagnostics coming soon. Much like the pattern we observed with Hims, I think that simply provides us a wider lens through which we can engage our customer base and bring them in early on their path. We’re also noticing, as Andrew pointed out, that diagnostics represents a major turning point in the company’s development, one that will pay off for both the Hims operation and the Hers operation. In my view, that will let us step in proactively to assist customers in handling their care. So even though we’re quite enthusiastic about that business on its own, its capacity to additionally shine a light on newer specialties we ought to be moving into, or to tailor treatments more precisely, I believe will do more than just boost retention — it will also expand the pool of subscribers we can connect with, not just inside Hers but inside Hims too.
Great. Then for my follow-up question, Yemi, I appreciate the detail you gave regarding the investments being made in the business. You mentioned something about a temporary pause when it comes to margins. Could margins actually shrink compared to last year in 2026 before the payoff becomes visible? Or is your view that even with all this spending, you're able to maintain your margin position going into next year?
Yes. My sense is that providing specific detail on 2026 at this point is premature. The teams are in the middle of actively working through those plans. Our approach follows an investment thesis comparable to what we've put to work before, much like 2023, when we pushed hard into investing. After roughly 2 quarters, we began seeing margins expand quickly. In this case, though, the set of levers available to us is much wider. What additionally provides conviction that these investments will be accretive is this: a number of them involve new capabilities and new specialties. We have a wide array of choices for verticalizing and optimizing unit economics across some of those new specialties, and that is what gives us a great deal of confidence. We're also putting money into areas such as talent, which tends to deliver exponential and asymmetric ROI once those people arrive and begin truly shifting the capabilities and the trajectory of what our technology platform is able to do — we see a significant amount of upside there; so my sense is that — giving you specifics around a 2026 guide at this point is a bit premature, but immense opportunity is visible to us, not only for growth levers in the future, but also for continued free cash flow generation plus the midterm expense of margin expansion that we witnessed in earlier quarters too.
Nice work on the quarter. On the cash flow subject, buybacks looked pretty robust this period. I'm just wondering how you weigh putting capital toward repurchases against, clearly, a sizable chunk of capital going to CapEx.
Right. We're fortunate to have extremely healthy free operating cash flow, plus a really solid cash position. Much like earlier quarters, whenever we believe there's a notable gap between what the company is worth on the market and what it's truly worth, we'll jump in and take action. So in the last quarter, those conditions did show up amid some of the swings we experienced in our stock. As a result, we chose to lean in. That being said, our top priority is always going to be putting money into the right areas to expand the business. That covers, as we mentioned earlier during the prepared remarks, broadening the range of personalized capabilities available to our patients, putting funds into the broader platform, and also into international markets; but we're simply fortunate to have such a sturdy balance sheet and such robust cash flow that we can pursue all of that and simultaneously capture gaps between intrinsic value and market value whenever they appear.
Understood. Then for my follow-up, when I consider — clearly, the press release mentioned your talks with Novo. Regarding your choice to lower the price on your GLPs and those discussions, I'm just wondering, what are the points being negotiated? Which topics of discussion are currently preventing that deal from being finalized? Or what would it take to close it? And then perhaps just considering the advantages and disadvantages of launching a Novo product here, both for your company and possibly for Novo?
Thank you, Brian. I can likely address that and, whether that's good or bad, not provide you with too much detail; however, there probably isn't a lot we can say about the particular conversations that have been happening with Novo. I believe we're thrilled to be in talks with them. And I think Mike is an excellent new leader for the organization. Broadly speaking, as I mentioned, we believe and have consistently stated that having a wide range of options for patients is ideal. We're a platform where we aim to provide people with the absolute right course of treatment, the right course of care and connect them with providers that can help them make those decisions. So from our standpoint, we are continually working with great innovative therapeutics, great innovative diagnostic companies, et cetera, next-gen biotech companies because we simply want to ensure that Hims & Hers genuinely does become the must-have in health care over time; and in the end, our job is to advocate on behalf of everyday people to hopefully deliver that to them at a price that is genuinely affordable to them and their family.
I want to touch base regarding the growth drivers in weight loss compared with what you originally anticipated for this year, and ask whether you remain on track to hit $725 million or exceed it, plus some background on how the compound and oral markets have each been shaping up.
Appreciate that question, Eric. Yeah, the brief response would be that strength keeps showing up in every piece of the weight loss specialty. Our oral business is still going strong and expanding at solid rates. A big part of that comes from wider eligibility criteria for the oral product, along with the chance to connect with more people who might feel hesitant about injectables. On top of that, the price point lets users get them for less money while still capturing more than half the benefits available on the injectable side. The GLP-1 product is another area where we keep seeing robust performance. So we're tracking toward that $725 million or greater goal we set out with at the start of this year.
Regarding the personalized compounded part, I understand you gave us a headwind figure of $20 million to $25 million. Was that — should I take that as 4Q? Also, could you describe the timing pattern as you moved the commercial doses off into 2Q, 3Q, and 4Q? Give us some clarity on that.
Yes. I believe much of the decline observed earlier in this year, from the first quarter to the second quarter, came mainly from moving subscribers off the commercially available dosages they had been taking. As we consider what will happen across the coming couple of quarters, what has essentially taken place is that we began shipping the GLP-1s in smaller batches. The net result is that our revenue gets recognized when shipments happen, rather than when consumers actually place their orders; therefore we still see very strong order velocity, yet since we ship on smaller cadences, that is essentially what is producing the headwind in the back half of this year that you see and that we anticipate will show up as the $20 million to $25 million headwind. What then occurs is that when those consumers renew, since they are on a smaller or shorter cadence, they renew more often across the year. Consequently, you get a stacking of cohorts that compounds quarter after quarter. Thus, our expectation is that once we reach the back half of next year, this dynamic will mostly normalize. So it has less to do with internal dynamics of the business and more to do with the adjustments to the shipping profile — the cadence profile — that we have for our subscribers.
Ryan, I'd like to begin with what's happening internationally. You now have Zava in the fold, and it's been roughly a quarter since that happened. What I'm wondering is this: now that you've had time to get to know that business better and you're spending more hours in markets abroad, to what degree are the Hims message and way of doing things finding traction beyond the United States? And in what ways is that shaping the plan for growing overseas? When you look at these markets, it sounds like the expansion is fairly aggressive. My sense is that every country has something distinctive that shifts how care gets delivered. So how do you — and what kind of spending is required to grow your clinician network as you keep extending your footprint around the world?
Andrew: Yeah. Thank you, Ryan. That's a terrific question. To me, Zava has been a fantastic initial step into the global arena — an acquisition that added value right away, with a superb team, superb operational strengths, and unbelievable things learned. They've already gone through a good number of markets, and watching that has been a real pleasure. Probably the biggest lesson so far is our belief that demand matches what we see in the U.S., and it makes no difference whether the system is national or insurance-based. What I mean is that frustration worldwide about getting access to excellent health care shows up no matter where someone lives. How long it takes to see specialists, how good the care is, how high-touch that care feels, how personalized it is, what it costs — honestly, all of that stays remarkably similar. So, because of that, and because we have confidence in what we consider a highly scalable operating model in the U.S. — I believe across the last 8 years we have refined what we see as the winning formula, the winning customer experience — we are now speeding up our capacity to carry that into really important markets. As we've said, Canada goes live before long; we're already deep in discussions with every significant generic manufacturer there, getting ready for generic semaglutide, which launches in 2026. We see Brazil as a genuinely compelling market where we'll devote time, and we'll likely deepen our investments further in the U.K., plus smaller markets such as Australia and Japan, and so on. Broadly speaking, we have a strong understanding of who the competitors are in these places, the differences among consumers, the local factors to keep in mind, the regulatory variations to keep in mind; because of that, the experience may differ somewhat from one to the next. As you suggested, there can be subtle differences in positioning, in marketing, or in what's offered. Still, on the whole, dissatisfaction with care and appetite for more high-touch, consumer-focused care is extremely widespread. So I'd say the people we've got, the drive we've got, plus perhaps a touch of insanity — only a small amount, you know — leave us ready to go after this and come out on top pretty fast in each one of those big markets.
That's useful context, thank you. As a follow-up, I'd like to ask about whole body lab testing — how it could be structured, packaged, or integrated alongside other offerings such as menopausal health, low T, and longevity as we move into next year. Unless we're wrong about this, based on what we've observed with the whole body testing market, particularly when done in a way that's cost effective and efficient for the consumer, it can often be a somewhat lower margin business when you look at gross margin; so first, is that consistent with what you're seeing? Or does that represent a risk if you launch a stand-alone whole-body lab testing offering? If that's the case, in what ways would you package it alongside maybe additional long-term services available through Hims, so that we could achieve what you might describe as a solid ratio of lifetime value to customer acquisition cost over the coming year or two?
Yeah, great question, Ryan. I think we're genuinely one of a kind as a business when it comes to making at-home lab testing, or lab testing generally, accessible to a broad population, because at our core we exist to help individuals improve their health, right? So looking at the big picture, there's no requirement for us to generate huge margins off of these tests, and that's what makes us different from basically every player in this space, including the large lab testing corporations and other rivals that offer diagnostics. At the end of the day, our business exists to make you feel your best, to help you move forward, to help you sharpen your sense of what personalized care ought to look like, and then to follow through on that. So, picking up on what you said, my guess is that as time goes on we'll end up with a strong blend of two things: standalone diagnostic offerings that generate leads into advanced treatment care, plus packaged diagnostic services within key treatment pathways, the way you've already seen happen with testosterone. My expectation is that this will keep broadening, so I believe there will be solid variety in that space. Down the road, though, what I'm aiming for — same as what we've pulled off before — is getting these products out into the market and, as time goes on, stacking the infrastructure vertically. We're already moving that direction thanks to the Trybe acquisition and some of our other bets in lab diagnostics. Get that up and running, build the systems around it, drive the cost way down — to levels that are honestly remarkable — so that on price you can genuinely undercut the vast majority of competitors while giving customers tremendous access to this kind of information. Then, in the end, become the partner they trust to take that information and turn it into something highly actionable and precise: what the next move ought to be, how personalized care should proceed, and holding their hand through that whole rhythm. So I'd say our position is genuinely one of a kind for doing precisely what you're describing, though I'd add there's a real difference with us, since keeping you healthy and keeping you ahead of these problems is what our core business is all about. On top of that, there's an opportunity for us to move this infrastructure vertically, which would let us bring lead-generation testing into the platform and take advantage of it there.
You've clearly gotten some solid efficiency out of your marketing efforts. I'm wondering whether anything has shifted when it comes to your marketing playbook or the way you go about it; and looking ahead to the new year, what's your thinking on marketing, particularly with the Super Bowl and the fact that you'll be going up against the tough comparison of your big win last year?
Yeah. Appreciate that question, Jonna. My sense is there are a few distinct levers through which we can generate really substantial marketing efficiency, both during the quarter and over the course of the year. The first is that we're clearly seeing meaningful efficiency arise because a growing share of our acquisition is arriving through organic channels and also through channels that cost less. As we continue to move deeper into the comprehensive full body testing we discussed earlier, I'd expect that trend to keep improving further and further as we refine and tune that engine; we're also seeing that with a growing number of users choosing personalized solutions, retention keeps getting stronger and stronger. And nearly all of our marketing dollars go either toward teaching consumers about the brand overall or bringing in new users. So when retention rises, we automatically capture efficiency there. What we're also seeing is that we have a broad range of growth opportunities ahead of us, or that will be arriving ahead of us over the next several quarters. That includes some of the newer specialties we've introduced <<inaudible>> menopausal support, boosting our footprint in markets where we've already proven successful such as the U.K., along with markets we will probably — that we intend to enter soon, such as Canada. So my view is we won't hold back when it comes to investing. With that said, we'll do it in a manner consistent with the capital allocation framework we've historically used, which requires a payback period of 1 year and essentially sets up the ecosystem to gain from greater and greater economies of scale. That way, once a couple of quarters have passed since those investments, you begin to see some of the levers we're benefiting from today as a result of investments we made previously. So I'd say looking at 2026, as I mentioned, the growth opportunity is likely even bigger than what we'd expected previously. So we'll lean in and put money behind that. Even so, I think the profile and our confidence in our capacity to reach the 2030 target of $6.5 billion of revenue and $1.3 billion of EBITDA is only growing.
That wraps up our session for today, everyone. We appreciate each of you being here, and at this point you're free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Hims & Hers Health, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Hims & Hers Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.